Literature DB >> 26997211

Application of the Surgical Apgar Score to Microvascular Head and Neck Reconstruction.

Kyle S Ettinger1, Eric J Moore2, Christine M Lohse3, Matthew D Reiland4, Jacob G Yetzer5, Kevin Arce6.   

Abstract

PURPOSE: The surgical Apgar score (SAS) is a recently devised risk-stratifying metric that relies on 3 intraoperative parameters to predict postoperative complications in surgical patients. The purpose of this study was to validate the SAS externally in a cohort of patients undergoing microvascular head and neck reconstruction with fibular free flaps.
MATERIALS AND METHODS: A retrospective cohort study of patients undergoing head and neck microvascular reconstruction with fibular free flaps was completed. The primary predictor variable was the calculated SAS. The primary outcome variable was the presence of medical and surgical complications occurring within 30 days of surgery. Basic demographic information, comorbidity indices, and perioperative parameters were abstracted as covariates. Medical and surgical complications were categorized as minor or major depending on severity level. Univariable and multivariable logistic regression models were used to evaluate associations with 30-day postoperative complications.
RESULTS: In 154 patients, the partial flap failure rate was 3% and there were no complete flap failures. There were 110 patients (71%) who developed at least 1 30-day postoperative complication and 51 (33%) who developed a major complication. The median SAS was 7. The SAS was not significantly associated with the presence of any 30-day postoperative complication (odds ratio [OR] = 1.02; 95% confidence interval [CI], 0.74-1.42; P = .89) or the presence of any major postoperative complication (OR = 0.08; 95% CI, 0.59-1.09; P = .16) in a univariable setting. The SAS did not achieve statistical significance after multivariable adjustment.
CONCLUSION: Despite validation in numerous other surgical specialties, the SAS might not be useful as a metric for risk stratification among patients undergoing major head and neck reconstruction with fibular free flaps.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26997211     DOI: 10.1016/j.joms.2016.02.013

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

1.  Utility of the Surgical Apgar Score in Head and Neck Squamous Cell Carcinoma.

Authors:  Andrew C Prince; Kristine E Day; Chee Paul Lin; Benjamin J Greene; William R Carroll
Journal:  Otolaryngol Head Neck Surg       Date:  2018-06-05       Impact factor: 3.497

Review 2.  The Reliability of Surgical Apgar Score in Predicting Immediate and Late Postoperative Morbidity and Mortality: A Narrative Review.

Authors:  Abhijit Nair; Aanchal Bharuka; Basanth Kumar Rayani
Journal:  Rambam Maimonides Med J       Date:  2018-01-29

3.  Prediction of perioperative complications after robotic-assisted radical hysterectomy for cervical cancer using the modified surgical Apgar score.

Authors:  Seon Hee Park; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  BMC Cancer       Date:  2018-09-21       Impact factor: 4.430

4.  The Surgical Apgar Score and frailty as outcome predictors in short- and long-term evaluation of fit and frail older patients undergoing elective laparoscopic cholecystectomy - a prospective cohort study.

Authors:  Kinga Mastalerz; Jakub Kenig; Urszula Olszewska; Cyprian Michalik
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-21       Impact factor: 1.195

5.  A comparative analysis using flowmeter, laser-Doppler |spectrophotometry, and indocyanine green-videoangiography for detection of vascular stenosis in free flaps.

Authors:  Thomas Mücke; Alexander Hapfelmeier; Leonard H Schmidt; Andreas M Fichter; Anastasios Kanatas; Klaus-Dietrich Wolff; Lucas M Ritschl
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.